NYSE:TMOLife Sciences
Is Thermo Fisher’s Datavant Deal and Clario Financing Altering The Investment Case For TMO?
Earlier in February 2026, Thermo Fisher Scientific’s PPD clinical research business announced a data collaboration with Datavant and completed a US$3.80 billions multi‑tranche senior notes offering, largely to help fund its pending acquisition of Clario Holdings.
This combination of enhanced real‑world data capabilities and fresh long-term financing underscores how Thermo Fisher is reinforcing its position across clinical research and evidence generation.
Next, we’ll examine how integrating...